| 4.17 -0.055 (-1.3%) | 05-12 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 5.13  |
1-year : | 5.53 |
| Resists | First : | 4.39 |
Second : | 4.74 |
| Pivot price | 4.29 |
|||
| Supports | First : | 3.83 |
Second : | 3.19 |
| MAs | MA(5) : | 4.24 |
MA(20) : | 4.3  |
| MA(100) : | 4.04 |
MA(250) : | 3.96 |
|
| MACD | MACD : | 0 |
Signal : | 0.1 |
| %K %D | K(14,3) : | 38.8 |
D(3) : | 38.5 |
| RSI | RSI(14): 49.2 |
|||
| 52-week | High : | 12.14 | Low : | 1.57 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ EVAX ] has closed above bottom band by 28.7%. Bollinger Bands are 52.9% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 11 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 4.36 - 4.38 | 4.38 - 4.4 |
| Low: | 4.09 - 4.12 | 4.12 - 4.14 |
| Close: | 4.13 - 4.18 | 4.18 - 4.21 |
Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies for cancers, bacterial diseases, and viral infections. The company develops EVX-01, a cancer immunotherapy that is in clinical Phase IIb trial for metastatic melanoma; EVX-02, a DNA-based cancer immunotherapy that is in Phase IIa trial for adjuvant melanoma; and EVX-03, a DNA-based immunotherapy for the treatment of various cancers. Its programs also include EVX-B1, EVX-B2, and EVX-V1, which are vaccines that are in pre-clinical stage for the treatment of bacterial and viral diseases. The company was incorporated in 2008 and is headquartered in Hørsholm, Denmark.
Tue, 28 Apr 2026
Evaxion Elevates CSO Birgitte Rønø to Dual CSO-COO Role to Drive AI Vaccine Strategy - The Globe and Mail
Fri, 24 Apr 2026
Evaxion A/S (EVAX) director discloses 2,376 Ordinary Shares via entity - Stock Titan
Fri, 17 Oct 2025
Evaxion reports 75% response rate in melanoma vaccine trial - Investing.com
Thu, 25 Sep 2025
$592M Potential Deal: Evaxion's AI-Powered Vaccine Platform Lands Major MSD Partnership for Novel Pathogen - Stock Titan
Thu, 25 Sep 2025
Evaxion Stock Climbs Amid Biotech Surge - StocksToTrade
Tue, 04 Feb 2025
Is It Too Late to Buy Evaxion? - timothysykes.com
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 8 (M) |
| Shares Float | 284 (M) |
| Held by Insiders | 17.4 (%) |
| Held by Institutions | 7.2 (%) |
| Shares Short | 31 (K) |
| Shares Short P.Month | 58 (K) |
| EPS | -1 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 2.03 |
| Profit Margin | -102.4 % |
| Operating Margin | -122.7 % |
| Return on Assets (ttm) | -28.3 % |
| Return on Equity (ttm) | -100.2 % |
| Qtrly Rev. Growth | -100 % |
| Gross Profit (p.s.) | 0.9 |
| Sales Per Share | 0.9 |
| EBITDA (p.s.) | -1.07 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -7 (M) |
| Levered Free Cash Flow | -4 (M) |
| PE Ratio | -4.18 |
| PEG Ratio | 0 |
| Price to Book value | 2.04 |
| Price to Sales | 4.61 |
| Price to Cash Flow | -5.26 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|